Strides, Incepta partner to boost women's health access in Africa

Strides Pharma Science Limited announced on October 17, 2025, that its wholly-owned subsidiary will market a WHO-prequalified generic version of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) across Africa. This initiative, under the brand Medogen SubQ, is a collaboration with Incepta Pharmaceuticals, and aims to expand access to affordable, quality contraceptive options.

The partnership reinforces Strides' commitment to women's health and global collaborations, leveraging the WHO prequalification of DMPA-SC. This allows for increased supply and more affordable procurement by health systems. This three-month contraceptive can be administered by healthcare workers or self-injected after training, addressing an unmet need among over 250 million women worldwide lacking modern contraception.

The collaboration will see Strides market the product Medogen SubQ in Africa, augmenting its existing women's health portfolio. The initiative is supported by the Children's Investment Fund Foundation (CIFF) and the Gates Foundation, marking a significant step in diversifying the supply of this essential medicine.